modelM02AA12
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Naproxen | |
| ATC code: | M02AA12 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 13 | L |
| clearance: | 0.12 | L/h |
| other parameters in model implementation | ||
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain, fever, swelling, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps. It is widely approved and in use globally.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult subjects, mixed sex, single oral dose.
References
Välitalo, P, et al., & Kokki, H (2012). Plasma and cerebrospinal fluid pharmacokinetics of naproxen in children. Journal of clinical pharmacology 52(10) 1516–1526. DOI:10.1177/0091270011418658 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22067196
Mendell, J, et al., & Samama, MM (2013). The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. Journal of cardiovascular pharmacology 62(2) 212–221. DOI:10.1097/FJC.0b013e3182970991 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23615159
Kubitza, D, et al., & Zuehlsdorf, M (2007). Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. British journal of clinical pharmacology 63(4) 469–476. DOI:10.1111/j.1365-2125.2006.02776.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/17100983
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)